Real-time Estimate
Cboe BZX
01:51:32 2024-05-21 pm EDT
|
5-day change
|
1st Jan Change
|
3.685
USD
|
+2.36%
|
|
-6.76%
|
-51.08%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
194.9
|
227.5
|
123
|
34.12
|
15.47
|
7.54
|
-
|
-
|
Enterprise Value (EV)
1 |
194.9
|
106.2
|
123
|
34.12
|
15.47
|
7.54
|
7.54
|
7.54
|
P/E ratio
|
-7.14
x
|
-3.96
x
|
-2.44
x
|
-0.87
x
|
-0.44
x
|
-0.31
x
|
-0.29
x
|
-0.26
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
10.1
x
|
3.35
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
10.1
x
|
3.35
x
|
EV / EBITDA
|
-
|
-
|
-2,091,834
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-7,400,189
x
|
-4,112,476
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,278
|
2,027
|
2,067
|
2,068
|
2,092
|
2,094
|
-
|
-
|
Reference price
2 |
152.5
|
112.2
|
59.50
|
16.50
|
7.395
|
3.600
|
3.600
|
3.600
|
Announcement Date
|
3/10/20
|
3/4/21
|
4/27/22
|
4/4/23
|
3/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.75
|
2.25
|
EBITDA
|
-
|
-
|
-58.8
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-34.55
|
-50.95
|
-59.98
|
-48.88
|
-41.69
|
-34.8
|
-36.73
|
-40.43
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-4,897.97%
|
-1,796.99%
|
Earnings before Tax (EBT)
1 |
-33.19
|
-50.6
|
-59.85
|
-48.04
|
-40.73
|
-34.74
|
-36.76
|
-40.46
|
Net income
1 |
-27.7
|
-42.92
|
-50.75
|
-40
|
-35.14
|
-32.97
|
-32.36
|
-36.02
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-4,314.64%
|
-1,601.02%
|
EPS
2 |
-21.35
|
-28.33
|
-24.41
|
-19.05
|
-16.85
|
-11.71
|
-12.47
|
-13.59
|
Free Cash Flow
|
-
|
-30.75
|
-29.91
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/4/21
|
4/27/22
|
4/4/23
|
3/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-19.7
|
-13.14
|
-6.285
|
-7.354
|
-21.55
|
-11.41
|
-8.004
|
-10.25
|
-11.58
|
-10.48
|
-8.676
|
-8.457
|
-8.52
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-19.68
|
-13.1
|
-6.126
|
-7.097
|
-21.19
|
-11.06
|
-7.777
|
-10.06
|
-11.41
|
-10.32
|
-8.584
|
-8.382
|
-8.457
|
-
|
-
|
Net income
1 |
-17.08
|
-10.55
|
-4.688
|
-5.38
|
-18.99
|
-9.816
|
-6.903
|
-8.315
|
-9.734
|
-8.664
|
-8.27
|
-8.188
|
-7.679
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-8.138
|
-5.020
|
-2.108
|
-2.674
|
-9.058
|
-4.679
|
-3.188
|
-4.036
|
-4.450
|
-4.118
|
-3.835
|
-3.126
|
-3.034
|
-3.839
|
-3.814
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/27/22
|
6/2/22
|
8/17/22
|
11/16/22
|
4/4/23
|
5/17/23
|
8/16/23
|
11/16/23
|
3/20/24
|
5/16/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
121
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-30.7
|
-29.9
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-49.2%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.5
|
0.08
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/4/21
|
4/27/22
|
4/4/23
|
3/20/24
|
-
|
-
|
-
|
Average target price
209
USD Spread / Average Target +5,705.56% Consensus |
1st Jan change
|
Capi.
|
---|
| -51.08% | 7.54M | | +7.80% | 115B | | +12.89% | 107B | | -13.36% | 22.31B | | -3.99% | 21.6B | | -6.52% | 18.23B | | -39.93% | 17.62B | | +6.80% | 14.26B | | +32.59% | 12.37B | | -28.07% | 8.28B |
Bio Therapeutic Drugs
|